(E/Z)-Zotiraciclib hydrochloride(Synonyms: (E/Z)-TG02 hydrochloride; (E/Z)-SB1317 hydrochloride)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

(E/Z)-Zotiraciclib hydrochloride (Synonyms: (E/Z)-TG02 hydrochloride; (E/Z)-SB1317 hydrochloride)

(E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride 是一种有效的 CDK2，JAK2 和 FLT3 抑制剂，用于癌症研究。

(E/Z)-Zotiraciclib hydrochloride(Synonyms: (E/Z)-TG02 hydrochloride; (E/Z)-SB1317 hydrochloride)

(E/Z)-Zotiraciclib hydrochloride Chemical Structure

CAS No. : 1321626-25-8

规格 价格 是否有货 数量
5 mg ￥1100 In-stock
10 mg ￥1500 In-stock
50 mg ￥4500 In-stock
100 mg ￥6500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

(E/Z)-Zotiraciclib hydrochloride 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Cell Cycle/DNA Damage Compound Library
  • Epigenetics Compound Library
  • Immunology/Inflammation Compound Library
  • JAK/STAT Compound Library
  • Kinase Inhibitor Library
  • Protein Tyrosine Kinase Compound Library
  • Stem Cell Signaling Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Differentiation Inducing Compound Library
  • Reprogramming Compound Library
  • Macrocyclic Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Liver Cancer Compound Library

生物活性

(E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride is a potent CDK2, JAK2, and FLT3 inhibitor[1].

IC50 & Target[1]

CDK2

 

JAK2

 

FLT3

 

分子量

408.92

Formula

C23H25ClN4O
CAS 号

1321626-25-8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
参考文献

  • [1]. William AD, et al. Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer. J Med Chem. 2012;55(1):169-196.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

发表回复